Akamai, Barnes Group, Varian Medical Systems, Siemens and Accuray highlighted as Zacks Bull and Bear of the Day

Akamai, Barnes Group, Varian Medical Systems, Siemens and Accuray highlighted
                      as Zacks Bull and Bear of the Day

PR Newswire

CHICAGO, June 17, 2013

CHICAGO, June 17, 2013 /PRNewswire/ -- Zacks Equity Research highlights Akamai
(Nasdaq:AKAM-Free Report) as the Bull of the Day and Barnes Group (NYSE:B-Free
Report) as the Bear of the Day. In addition, Zacks Equity Research provides
analysis ontheVarian Medical Systems, Inc. (NYSE:VAR-Free Report), Siemens AG
(NYSE:SI-Free Report) and Accuray Incorporated (Nasdaq:ARAY-Free Report).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Here is a synopsis of all five stocks:

Bull of the Day:

If you've ever shopped online, downloaded music, watched a web video or
connected to work remotely, you've probably used Akamai's (Nasdaq:AKAM-Free
Report) cloud platform. We ensure the best online experience on any device,
anywhere.

Akamai helps enterprises accelerate innovation in the hyperconnected world by
removing the complexities of technology so you can focus on driving your
business faster forward. We enable enterprises to capitalize on market
opportunities presented by trends like mobile and cloud while overcoming the
challenges presented by security threats and the need to reach users globally.

The Akamai Intelligent Platform™ reaches globally and delivers locally,
providing our customers with unmatched reliability, security and visibility
into their online business.

Bear of the Day:

Sometimes you can have a good company that finds its stock a bit ahead of
itself, which is what I think we are seeing here in Barnes Group, today's Bear
of the Day.

If you are not familiar, Barnes Group (NYSE:B-Free Report) (Zacks Rank #5) is
an international aerospace and industrial manufacturing and services provider,
serving a wide range of end markets and customers. The products and services
provided by the company are used in far-reaching applications that provide
transportation, communication, manufacturing and technology to the world.

Many of their products are highly engineered, high quality (high price)
products for those industries. In a world that is seeing slowing growth on
the downswing rather than on the rise, I am concerned that the 50% rise in
share price and 19 times earnings multiple might be a little rich. I have no
doubt the company will continue to sell its components, but their growth looks
questionable in the second quarter.

Barnes generates roughly 20% of its sales in Europe, 18% in Asia and 62% in
the Americas.

Barnes Group reported Q1 adjusted earnings per share of 40 cents, up roughly
25% year over year in late April; the results fell 11.1% short of the Zacks
Consensus Estimate for 45 cents.

Additional content:

Varian Links with Siemens Systems

Oncology and X-Ray products company Varian Medical Systems, Inc.
(NYSE:VAR-Free Report), and Siemens Healthcare, a part of Siemens AG
(NYSE:SI-Free Report), recently revealed that technicians at The Ohio State
University are utilizing Varian software to conduct radiotherapy sessions with
linear accelerators manufactured by Siemens. The two companies have created an
interface that links the Aria system from Varian with certain equipment of
Siemens.

In Mar 2013, Siemens was granted 510(k) clearance from the Food and Drug
Administration for connectivity between Aria software and two of its linear
accelerators.

As per Varian, its software can function with 80% of Siemens hardware. In
fact, a large proportion of Siemens locations may utilize Aria to handle
different forms of care.

Siemens Healthcare is a leader in diagnostics, medical imaging and other
health care areas. The company offers a wide range of offerings ranging from
prevention to diagnosis.

Varian is a leading manufacturer of integrated radiotherapy systems for cancer
treatment and a premier supplier of X-Ray tubes for diagnostic imaging
applications. The company operates in a technology-driven environment where
success depends on the use of new technology, product development and
upgrades. In the radiation oncology market, Varian competes with Accuray
Incorporated (Nasdaq:ARAY-Free Report).

The company is poised to increase its market share in radiation oncology. It
currently enjoys a healthy demand for its coveted TrueBeam technology, which
has meaningfully contributed to its net order oncology growth. Varian's
TrueBeam is designed to treat tumors with beams of high speed and precision.
It incorporates several technological innovations such as patient positioning
and managing his/her motion. Given its high intensity nature, TrueBeam can
dispense strong dosage over twice as fast as that possible with earlier
equipment.

Get today's Zacks #1 Stock of the Day with your free subscription to Profit
from the Pros newsletter:

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Click here to subscribe to this
free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the
Pros.

Get the full Report on AKAM - FREE

Get the full Report on B - FREE

Get the full Report on VAR - FREE

Get the full Report on SI - FREE

Get the full Report on ARAY - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such
affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Zacks.com provides investment resources and informs you of these resources,
which you may choose to use in making your own investment decisions. Zacks is
providing information on this resource to you subject to the Zacks "Terms and
Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.